Skip to main content
. 2017 Nov 14;8(65):108970–108980. doi: 10.18632/oncotarget.22447

Figure 1. (A) Receiver operating characteristic curves of the HBV-ACLFD model in predicting mortality in the derivation cohort.

Figure 1

The HBV-ACLFD model had discrimination (AUROC=0.848; 95% CI: 0.793 to 0.902). (B) Receiver operating characteristic curves of the HBV-ACLFD model in predicting mortality in the validation cohort. The HBV-ACLFD model retained a good discrimination when applied to a validation cohort (AUROC=0.813; 95% CI: 0.720 to 0.905). The Hosmer-Lemeshow goodness-of-fit test for HBV-ACLFD model has been performed (p=0.612).